News
PTCT
--
0.00%
--
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 11, 2021 it approved non-statutory stock options to purchase an aggregate of 118,350 shares of its common stock and 30,835 restricted stock units ("RSUs"), each representing the right to re...
PR Newswire · 2d ago
A Look At The Intrinsic Value Of PTC Therapeutics, Inc. (NASDAQ:PTCT)
In this article we are going to estimate the intrinsic value of PTC Therapeutics, Inc. ( NASDAQ:PTCT ) by taking the...
Simply Wall St. · 06/11 11:10
Pre-symptomatic Infants with Spinal Muscular Atrophy Achieved Same Motor Milestones as Healthy Children After Treatment with Evrysdi™ in RAINBOWFISH
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced positive interim results from the ongoing RAINBOWFISH trial that demonstrated pre-symptomatic infants with spinal muscular atrophy (SMA) treated with Evrysdi were able to reach motor mil...
PR Newswire - PRF · 06/11 05:00
PTC Therapeutics Says Interim Study Results Show Potential of Spinal Muscular Atrophy Treatment Evrysdi
MT Newswires · 06/11 03:53
BRIEF-Health And Human Services Expert Mary L. Smith Joins Ptc Therapeutics' Board Of Directors
reuters.com · 06/09 12:22
Health and Human Services Expert Mary L. Smith Joins PTC Therapeutics' Board of Directors
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the election of Mary L. Smith to the Company's Board of Directors. Ms. Smith has previously served as the Principal Deputy Director and CEO equivalent at the Indian Health Service, a $6 billion division...
PR Newswire · 06/09 12:00
PTC Therapeutics' (PTCT) PTC923 Gets Orphan Drug Tag in US & EU
Zacks.com · 05/27 14:23
BRIEF-PTC Therapeutics Inc - U.S FDA And European Commission Have Granted Orphan Drug Designation For PTC923
reuters.com · 05/26 12:32
PTC Therapeutics Reports Orphan Drug Designations Of PTC923 For Treatment Of Hyperphenylalaninemia
PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that both the United States Food and Drug Administration (FDA) and European Commission (EC) have granted Orphan Drug Designation (ODD) for PTC923 for the treatment of
Benzinga · 05/26 12:06
PTC Therapeutics Announces Orphan Drug Designations of PTC923 for the Treatment of Hyperphenylalaninemia
, /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that both the United States Food and Drug Administration (FDA) and European Commission (EC) have granted Orphan Drug Designation (ODD) for PTC923 for the treatment of patients with hy...
PR Newswire - PRF · 05/26 12:01
PTC Therapeutics' PTC923 Drug Candidate Gets Orphan Drug Designation From FDA, European Commission
MT Newswires · 05/26 08:49
PTC Therapeutics to Participate at Upcoming Virtual Investor Conference
, /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the following conference:
PR Newswire - PRF · 05/19 12:00
New Data Shows Devastating Impact of AADC Deficiency on Caregivers
, /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced data from the first study on the impact of caring for a child with the ultra-rare genetic disorder, aromatic L-Amino acid decarboxylase deficiency (AADC-d). Results show that caregive...
PR Newswire - PRF · 05/17 12:00
--Truist Securities Adjusts Price Target on PTC Therapeutics to $65 From $75, Maintains Buy Rating
MT Newswires · 05/17 11:06
Sofinnova Ventures Inc Buys Eli Lilly and Co, NextCure Inc, Align Technology Inc, Sells ...
GuruFocus News · 05/16 07:25
Rtw Investments, Llc Buys S&P 500 ETF TRUST ETF, Quidel Corp, Tarsus Pharmaceuticals Inc, ...
GuruFocus News · 05/16 07:09
The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 13)
Benzinga · 05/14 11:59
Global Cystic Fibrosis Drugs Market size 2021, status, industry recent trend, demand, business growth, forecast to 2026
May 12, 2021 (The Expresswire) -- Global “Cystic Fibrosis Drugs Market” can help you discover multiple perspectives that will help you answer your questions...
The Express Wire · 05/12 14:37
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11)
Benzinga · 05/12 12:57
Spinal Muscular Atrophy Treatment Market Trend, Segmentation and Opportunities Forecast To 2028
May 12, 2021 (AmericaNewsHour) -- Research Nester published a report titled “Spinal Muscular Atrophy Treatment Market: Global Demand Analysis &...
AmericaNewsHour · 05/12 05:29
Webull provides a variety of real-time PTCT stock news. You can receive the latest news about PTC Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About PTCT
PTC Therapeutics, Inc. is a science-driven global biopharmaceutical company. The Company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. The Company have a portfolio pipeline that includes commercial products as well as product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The Company have two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD). The Company have a pipeline of gene therapy product candidates for rare monogenic diseases that affect the central nervous system (CNS), including PTC-AADC for the treatment of Aromatic L-Amino Acid Decarboxylase (AADC) and PTC923 for phenylketonuria (PKU) diseases.